Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Capricor Therapeutics, Inc. (CAPR)
USD19.85
-0.83 (-4.01%)
US NASDAQ Healthcare Biotechnology
Address
10865 Road to the Cure 92121
San Diego, CA, US
San Diego, CA, US
CEO
Linda Marbán
Website
capricor.com
IPO
2007-02-13
CIK 1133869 ISIN US14070B3096
Description
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD19.85
-0.83 (-4.01%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.37
Float Shares
37.80M
Free Float %
82.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.19% | -7.16% | +1.03% | +33.16% | +436.97% | +9.22% | +343.32% | +682.13% | +829.79% | -11.96% | -93.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (10 ratings, all time)
Buy
Price Targets & DCF
Current price
19.85
Low
45.00
+126.7%
Consensus
52.71
+165.5%
Median
50.00
+151.9%
High
62.00
+212.3%
DCF (Unlevered)
5.71
-71.2%
DCF (Levered)
5.74
-71.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 7 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
62.00
+212.3%
|
| Last Year | 10 |
42.60
+114.6%
|
| All Time | 16 |
31.38
+58.1%
|
Quality scores
Altman Z-Score
16.11
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%-96.5% Q1'26: -11.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-1,256.3% Q1'26: -1.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+32.0% Q1'26: +25.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.19× Q1'26: -100.51× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 7 EPS Ana. |
Dec 2027 7 Rev. Ana. 6 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.78M
est: 5.49M (-31.3%)
|
3.19M
est: 4.10M (-22.2%)
|
2.67M
est: 2.80M (-4.8%)
|
1.67M
est: 1.16M (+43.9%)
|
1.01M
est: 841.5K (+19.4%)
|
310.3K
est: 252.0K (+23.1%)
|
244.9K
est: 222.5K (+10.1%)
|
2.55M
est: 1.59M (+60.0%)
|
25.18M
est: 27.15M (-7.3%)
|
22.27M
est: 20.97M (+6.2%)
|
—
est: 655.6K (-100.0%)
|
122.81M
754.1K – 249.93M
+18,634.1% YoY
|
102.69M
12.11M – 254.33M
-16.4% YoY
|
245.48M
15.30M – 505.70M
+139.0% YoY
|
399.80M
24.91M – 823.61M
+62.9% YoY
|
623.25M
38.84M – 1.28B
+55.9% YoY
|
| EBITDA |
-12.50M
est: -5.40M (-131.5%)
|
-18.34M
est: -4.03M (-355.1%)
|
2.97M
est: -2.75M (+208.1%)
|
-15.17M
est: -1.14M (-1,228.9%)
|
-7.56M
est: -827.0K (-814.4%)
|
-13.55M
est: -247.7K (-5,369.7%)
|
-20.69M
est: -218.7K (-9,363.2%)
|
-29.16M
est: -1.57M (-1,760.9%)
|
-23.01M
est: -15.82M (-45.4%)
|
-41.14M
est: -12.22M (-236.6%)
|
-108.14M
est: -382.0K (-28,206.6%)
|
-71.57M
-145.65M – -439.5K
-18,634.1% YoY
|
-59.85M
-148.22M – -7.06M
+16.4% YoY
|
-143.06M
-294.71M – -8.91M
-139.0% YoY
|
-232.99M
-479.98M – -14.52M
-62.9% YoY
|
-363.21M
-748.24M – -22.63M
-55.9% YoY
|
| EBIT |
-12.61M
est: -5.44M (-131.6%)
|
-16.98M
est: -4.06M (-317.7%)
|
2.83M
est: -2.78M (+202.0%)
|
-15.33M
est: -1.15M (-1,231.2%)
|
-7.73M
est: -834.1K (-827.2%)
|
-13.69M
est: -249.8K (-5,380.4%)
|
-20.94M
est: -220.6K (-9,393.5%)
|
-29.70M
est: -1.58M (-1,778.7%)
|
-24.08M
est: -16.05M (-50.0%)
|
-42.56M
est: -12.40M (-243.2%)
|
-108.14M
est: -387.6K (-27,800.2%)
|
-72.61M
-147.78M – -445.9K
-18,634.1% YoY
|
-60.72M
-150.38M – -7.16M
+16.4% YoY
|
-145.14M
-299.00M – -9.04M
-139.0% YoY
|
-236.38M
-486.97M – -14.73M
-62.9% YoY
|
-368.50M
-759.15M – -22.96M
-55.9% YoY
|
| Net Income |
-12.86M
est: -281.75M (+95.4%)
|
-18.81M
est: -346.91M (+94.6%)
|
2.43M
est: -190.18M (+101.3%)
|
-15.19M
est: -202.51M (+92.5%)
|
-7.64M
est: -69.21M (+89.0%)
|
-13.66M
est: -30.99M (+55.9%)
|
-20.02M
est: -28.18M (+28.9%)
|
-29.02M
est: -29.23M (+0.7%)
|
-22.29M
est: -27.95M (+20.2%)
|
-40.47M
est: -46.17M (+12.3%)
|
-105.04M
est: -98.17M (-7.0%)
|
-18.22M
-3.34B – 3.36B
+81.4% YoY
|
-32.77M
-71.43M – 35.40M
-79.9% YoY
|
109.58M
43.76M – 207.85M
+434.4% YoY
|
193.81M
-42.44M – 460.91M
+76.9% YoY
|
328.60M
-71.96M – 781.45M
+69.5% YoY
|
| SGA |
4.37M
est: 59.56M (-92.7%)
|
4.93M
est: 44.46M (-88.9%)
|
4.76M
est: 30.36M (-84.3%)
|
4.93M
est: 12.59M (-60.8%)
|
3.60M
est: 9.12M (-60.6%)
|
5.54M
est: 2.73M (+102.9%)
|
7.61M
est: 2.41M (+215.5%)
|
10.43M
est: 17.29M (-39.7%)
|
12.81M
est: 202.82M (-93.7%)
|
14.87M
est: 156.67M (-90.5%)
|
23.69M
est: 4.90M (+383.7%)
|
917.37M
5.63M – 1.87B
+18,634.1% YoY
|
767.09M
90.47M – 1.90B
-16.4% YoY
|
1.83B
114.26M – 3.78B
+139.0% YoY
|
2.99B
186.09M – 6.15B
+62.9% YoY
|
4.66B
290.10M – 9.59B
+55.9% YoY
|
| EPS |
-8.09
est: -8.00 (-1.1%)
|
-10.14
est: -9.85 (-2.9%)
|
1.00
est: -5.40 (+118.5%)
|
-5.17
est: -5.75 (+10.1%)
|
-2.06
est: -1.97 (-4.8%)
|
-0.88
est: -0.88 (+0.0%)
|
-0.87
est: -0.80 (-8.8%)
|
-1.18
est: -1.22 (+3.0%)
|
-0.83
est: -0.93 (+11.1%)
|
-1.15
est: -1.19 (+3.4%)
|
-2.26
est: -2.13 (-6.0%)
|
-0.30
-71.79 – 72.39
+86.1% YoY
|
-0.53
-1.54 – 0.76
-79.5% YoY
|
1.89
0.94 – 4.47
+454.5% YoY
|
4.17
-0.91 – 9.92
+120.9% YoY
|
7.07
-1.55 – 16.81
+69.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-101.25M
OE per share TTM
-2.16
Owner's Yield
-6.50%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
88.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
39
Total invested
43.08M
Insider transactions (90d)
2
Beneficial owners (>5%)
33
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cedars-Sinai Medical Center | 4.26M | 18.70% | 4.26M | — | 4.26M | — | CO | California | 2017-05-12 | ↗ |
| 2 | Eduardo Marbán, M.D., Ph.D. | 3.16M | 27.10% | 3.16M | — | 3.16M | 10.00 | IN | United States | 2013-12-03 | ↗ |
| 3 | Highbridge Capital Management, LLC | 2.79M | 9.10% | — | 2.79M | — | — | IA, OO | State of Delaware | 2024-02-07 | ↗ |
| 4 | Nippon Shinyaku Co., Ltd. | 2.15M | 6.97% | 2.15M | — | 2.15M | — | FI | Japan | 2023-10-17 | ↗ |
| 5 | Jon M. Plexico | 2.11M | 4.70% | — | 2.11M | — | — | IN | California | 2013-08-07 | ↗ |
| 6 | L.P. | 2.11M | 4.70% | — | 2.11M | — | — | PN | California | 2013-08-07 | ↗ |
| 7 | LLC | 2.11M | 4.70% | — | 2.11M | — | — | HC | California | 2013-08-07 | ↗ |
| 8 | Lynch | 2.11M | 4.70% | — | 2.11M | — | — | IN | California | 2013-08-07 | ↗ |
| 9 | Larry N. Feinberg | 2.00M | 9.78% | — | 2.00M | — | 2.00M | IN | United States | 2021-02-08 | ↗ |
| 10 | Oracle Associates, LLC | 2.00M | 9.78% | — | 2.00M | — | 2.00M | PN | United States | 2021-02-08 | ↗ |
| 11 | Oracle Investment Management, Inc. | 2.00M | 9.78% | — | 2.00M | — | 2.00M | CO | United States | 2021-02-08 | ↗ |
| 12 | Frank Litvack | 1.82M | 10.10% | 1.82M | — | 1.82M | 10.00 | IN | United States | 2015-03-13 | ↗ |
| 13 | (1) BlackRock, Inc. | 1.75M | 5.40% | 1.74M | — | 1.75M | — | HC | Delaware | 2024-11-12 | ↗ |
| 14 | LOUIS GRASMICK | 1.54M | 8.40% | 404.3K | 1.14M | 404.3K | 10.00 | IN | United States | 2016-03-21 | ↗ |
| 15 | Oracle Partners, L.P. | 1.48M | 7.25% | — | 1.48M | — | 1.48M | PN | United States | 2021-02-08 | ↗ |
| 16 | LOUIS MANZO | 1.18M | 6.40% | 1.18M | — | 1.18M | 10.00 | IN | United States | 2016-03-21 | ↗ |
| 17 | NANCY GRASMICK | 1.14M | 6.30% | — | 1.14M | — | 10.00 | IN | United States | 2016-03-21 | ↗ |
| 18 | GRANT GRASMICK | 1.06M | 5.90% | — | 1.06M | — | 10.00 | IN | United States | 2016-03-21 | ↗ |
| 19 | NANCELOU, INC. | 1.06M | 5.90% | 1.06M | — | 1.06M | 10.00 | CO | Maryland | 2016-03-21 | ↗ |
| 20 | Linda Marbán, Ph.D. | 969.1K | 5.20% | 959.9K | 9.2K | 959.9K | 10.00 | IN | United States | 2016-03-21 | ↗ |
| 21 | CONISTON CORPORATION | 638.2K | 3.60% | 638.2K | — | 638.2K | 10.00 | CO | Maryland | 2016-03-21 | ↗ |
| 22 | BARCLAYS GLOBAL INVESTORS, NA. | 369.7K | 2.65% | 1.32M | — | 1.32M | — | BK | USA | 2014-02-14 | ↗ |
| 23 | Oracle Ten Fund, L.P. | 310.6K | 1.52% | — | 310.6K | — | 310.6K | PN | United States | 2021-02-08 | ↗ |
| 24 | Armistice Capital Master Fund Ltd. | 243.2K | 4.99% | — | 243.2K | — | 243.2K | CO | Delaware | 2019-12-27 | ↗ |
| 25 | Armistice Capital, LLC | 243.2K | 4.99% | — | 243.2K | — | 243.2K | IA, OO | Delaware | 2019-12-27 | ↗ |
| 26 | Steven Boyd | 243.2K | 4.99% | — | 243.2K | — | 243.2K | HC, IN | Delaware | 2019-12-27 | ↗ |
| 27 | Oracle Institutional Partners, L.P. | 207.0K | 1.01% | — | 207.0K | — | 207.0K | PN | United States | 2021-02-08 | ↗ |
| 28 | Charles E. Davidson | 52.1K | 0.45% | — | 52.1K | — | 10.00 | IN | United States | 2013-12-05 | ↗ |
| 29 | Joseph M. Jacobs | 52.1K | 0.45% | — | 52.1K | — | 10.00 | IN | United States | 2013-12-05 | ↗ |
| 30 | Wexford Capital LP | 52.1K | 0.45% | — | 52.1K | — | 10.00 | PN | Delaware | 2013-12-05 | ↗ |
| 31 | Wexford GP LLC | 52.1K | 0.45% | — | 52.1K | — | 10.00 | OO | Delaware | 2013-12-05 | ↗ |
| 32 | Iota Investors LLC | 38.2K | 0.33% | — | 38.2K | — | 10.00 | OO | Delaware | 2013-12-05 | ↗ |
| 33 | Wexford Spectrum Investors LLC | 13.9K | 0.12% | — | 13.9K | — | 10.00 | OO | Delaware | 2013-12-05 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
39
-111 vs prev Q
New positions
15
Closed positions
114
Increased
26
Reduced
6
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 2.85M -19.2K (-0.7%) | 82.28M +61.6M (+297.6%) | 6.24% -0.043 pp | 0.00% +0.001 pp | USD14.57 +98.1% | 6 qtrs — |
| 2 | VANGUARD GROUP INC | 2.56M +355.2K (+16.1%) | 73.94M +58.0M (+364.7%) | 5.60% +0.776 pp | 0.00% +0.001 pp | USD10.64 +171.2% | 27 qtrs — |
| 3 | POINT72 ASSET MANAGEMENT, L.P. | 1.84M +1.7M (+1,451.4%) | 53.10M +52.2M (+6,110.1%) | 4.02% +3.765 pp | 0.06% +0.058 pp | USD27.46 +5.1% | 2 qtrs — |
| 4 | SUVRETTA CAPITAL MANAGEMENT, LLC | 1.79M +1.8M (+100.0%) | 51.53M +51.5M (+100.0%) | 3.91% +3.906 pp | 1.06% +1.056 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 5 | TANG CAPITAL MANAGEMENT LLC | 1.70M +1.7M (+100.0%) | 49.06M +49.1M (+100.0%) | 3.72% +3.719 pp | 2.42% +2.424 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 6 | RA CAPITAL MANAGEMENT, L.P. | 1.51M +1.5M (+100.0%) | 43.52M +43.5M (+100.0%) | 3.30% +3.298 pp | 0.45% +0.446 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 7 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.43M +816.1K (+132.5%) | 41.33M +36.9M (+830.7%) | 3.13% +1.785 pp | 0.00% +0.004 pp | USD20.95 +37.8% | 23 qtrs — |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.02M +55.8K (+5.8%) | 29.37M +22.4M (+323.5%) | 2.23% +0.122 pp | 0.00% +0.001 pp | USD8.69 +232.1% | 27 qtrs — |
| 9 | FMR LLC | 922.6K +898.9K (+3,794.6%) | 26.63M +26.5M (+15,489.6%) | 2.02% +1.966 pp | 0.00% +0.001 pp | USD28.50 +1.3% | 8 qtrs — |
| 10 | CITADEL ADVISORS LLC | 902.0K +751.5K (+499.2%) | 26.03M +24.9M (+2,298.6%) | 1.97% +1.644 pp | 0.00% +0.004 pp | USD25.25 +14.3% | 25 qtrs — |
| 11 | STATE STREET CORP | 829.5K +28.2K (+3.5%) | 23.94M +18.2M (+314.4%) | 1.81% +0.061 pp | 0.00% +0.001 pp | USD12.84 +124.8% | 19 qtrs — |
| 12 | DARWIN GLOBAL MANAGEMENT, LTD. | 800.0K +800.0K (+100.0%) | 23.17M +23.2M (+100.0%) | 1.75% +1.750 pp | 0.47% +0.469 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 13 | MILLENNIUM MANAGEMENT LLC | 682.3K +479.9K (+237.0%) | 19.69M +18.2M (+1,249.0%) | 1.49% +1.050 pp | 0.01% +0.008 pp | USD22.75 +26.9% | 10 qtrs — |
| 14 | SOLEUS CAPITAL MANAGEMENT, L.P. | 646.4K +646.4K (+100.0%) | 18.65M +18.7M (+100.0%) | 1.41% +1.414 pp | 0.69% +0.688 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 15 | MORGAN STANLEY | 585.8K +34.1K (+6.2%) | 16.91M +12.9M (+325.1%) | 1.28% +0.075 pp | 0.00% +0.001 pp | USD13.13 +119.8% | 26 qtrs — |
| 16 | IKARIAN CAPITAL, LLC | 578.0K +313.4K (+118.4%) | 16.68M +14.8M (+774.3%) | 1.26% +0.685 pp | 1.30% +1.110 pp | USD18.95 +52.3% | 2 qtrs — |
| 17 | GOLDMAN SACHS GROUP INC | 448.0K +272.3K (+155.1%) | 12.93M +11.7M (+920.9%) | 0.98% +0.596 pp | 0.00% +0.001 pp | USD21.02 +37.3% | 18 qtrs — |
| 18 | DG CAPITAL MANAGEMENT, LLC | 414.0K -56.4K (-12.0%) | 11.95M +8.6M (+252.3%) | 0.91% -0.124 pp | 5.24% +4.064 pp | USD7.21 +300.3% | 2 qtrs — |
| 19 | — | 400.0K +400.0K (+100.0%) | 11.54M +11.5M (+100.0%) | 0.88% +0.875 pp | 4.23% +4.231 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 20 | JPMORGAN CHASE & CO | 369.1K +179.3K (+94.5%) | 10.65M +9.3M (+678.5%) | 0.81% +0.392 pp | 0.00% +0.001 pp | USD19.29 +49.6% | 8 qtrs — |
| 21 | BALYASNY ASSET MANAGEMENT L.P. | 353.0K +353.0K (+100.0%) | 10.19M +10.2M (+100.0%) | 0.77% +0.772 pp | 0.01% +0.013 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 22 | NORTHERN TRUST CORP | 350.6K -1.9K (-0.5%) | 10.12M +7.6M (+298.1%) | 0.77% -0.004 pp | 0.00% +0.001 pp | USD11.25 +156.5% | 23 qtrs — |
| 23 | BARCLAYS PLC | 328.9K +244.8K (+291.1%) | 9.49M +8.9M (+1,465.4%) | 0.72% +0.535 pp | 0.00% +0.002 pp | USD24.02 +20.1% | 3 qtrs — |
| 24 | BOXER CAPITAL MANAGEMENT, LLC | 325.0K +325.0K (+100.0%) | 9.38M +9.4M (+100.0%) | 0.71% +0.711 pp | 2.05% +2.053 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 25 | D. E. SHAW & CO., INC. | 315.0K +250.0K (+384.6%) | 9.09M +8.6M (+1,839.8%) | 0.69% +0.547 pp | 0.01% +0.005 pp | USD24.39 +18.3% | 2 qtrs — |
| 26 | DIADEMA PARTNERS LP | 312.3K +12.3K (+4.1%) | 9.01M +6.8M (+316.7%) | 0.68% +0.027 pp | 1.55% +0.999 pp | USD8.06 +258.1% | 5 qtrs — |
| 27 | LMR PARTNERS LLP | 304.7K -25.0K (-7.6%) | 8.79M +6.4M (+269.9%) | 0.67% -0.055 pp | 0.02% +0.006 pp | USD11.37 +153.8% | 6 qtrs — |
| 28 | J. GOLDMAN & CO LP | 277.9K +142.9K (+105.9%) | 8.02M +7.0M (+724.0%) | 0.61% +0.313 pp | 0.21% +0.187 pp | USD18.34 +57.4% | 2 qtrs — |
| 29 | RTW INVESTMENTS, LP | 250.0K +250.0K (+100.0%) | 7.22M +7.2M (+100.0%) | 0.55% +0.547 pp | 0.07% +0.072 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 30 | QUINN OPPORTUNITY PARTNERS LLC | 242.9K +114.5K (+89.3%) | 7.01M +6.1M (+657.5%) | 0.53% +0.251 pp | 0.30% +0.230 pp | USD17.42 +65.7% | 2 qtrs — |
| 31 | PERCEPTIVE ADVISORS LLC | 242.1K +242.1K (+100.0%) | 6.99M +7.0M (+100.0%) | 0.53% +0.530 pp | 0.12% +0.125 pp | USD28.86 +0.0% | 3 qtrs — |
| 32 | UBS GROUP AG | 238.2K +113.5K (+91.0%) | 6.87M +6.0M (+664.6%) | 0.52% +0.248 pp | 0.00% +0.001 pp | USD19.22 +50.2% | 8 qtrs — |
| 33 | PALO ALTO INVESTORS LP | 226.3K +226.3K (+100.0%) | 6.53M +6.5M (+100.0%) | 0.50% +0.495 pp | 0.91% +0.909 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 34 | CAPTION MANAGEMENT, LLC | 223.8K -223.7K (-50.0%) | 6.46M +3.2M (+100.2%) | 0.49% -0.490 pp | 0.04% +0.019 pp | USD9.86 +192.7% | 7 qtrs — |
| 35 | WOODLINE PARTNERS LP | 219.1K +209.0K (+2,065.5%) | 6.32M +6.2M (+8,568.0%) | 0.48% +0.457 pp | 0.02% +0.024 pp | USD28.14 +2.6% | 5 qtrs — |
| 36 | MOODY ALDRICH PARTNERS LLC | 208.8K +208.8K (+100.0%) | 6.02M +6.0M (+100.0%) | 0.46% +0.457 pp | 1.12% +1.124 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 37 | RAYMOND JAMES FINANCIAL INC | 195.4K +4.1K (+2.1%) | 5.64M +4.3M (+308.9%) | 0.43% +0.009 pp | 0.00% +0.001 pp | USD7.79 +270.5% | 4 qtrs — |
| 38 | BOOTHBAY FUND MANAGEMENT, LLC | 190.7K +87.0K (+83.9%) | 5.50M +4.8M (+635.9%) | 0.42% +0.190 pp | 0.08% +0.071 pp | USD17.08 +69.0% | 2 qtrs — |
| 39 | HBK SORCE ADVISORY LLC | 203.7K +33.1K (+19.4%) | 5.04M +3.9M (+341.3%) | 0.45% +0.072 pp | 0.12% +0.088 pp | USD12.33 +134.1% | 4 qtrs — |
| 40 | NATIONAL BANK OF CANADA /FI/ | 143.5K -254.2K (-63.9%) | 4.14M +1.3M (+44.4%) | 0.31% -0.556 pp | 0.00% +0.001 pp | USD8.36 +245.2% | 3 qtrs — |
| 41 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 130.0K +130.0K (+100.0%) | 3.75M +3.8M (+100.0%) | 0.28% +0.284 pp | 0.01% +0.006 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 42 | WELLINGTON MANAGEMENT GROUP LLP | 128.3K -4.0K (-3.1%) | 3.70M +2.7M (+288.0%) | 0.28% -0.009 pp | 0.00% +0.001 pp | USD10.89 +165.0% | 5 qtrs — |
| 43 | AMERIPRISE FINANCIAL INC | 125.2K +125.2K (+100.0%) | 3.61M +3.6M (+100.0%) | 0.27% +0.274 pp | 0.00% +0.001 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 44 | MARSHALL WACE, LLP | 121.9K +22.8K (+23.0%) | 3.52M +2.8M (+392.4%) | 0.27% +0.050 pp | 0.00% +0.003 pp | USD13.05 +121.1% | 7 qtrs — |
| 45 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 119.4K -933.0 (-0.8%) | 3.44M +2.6M (+297.2%) | 0.26% -0.002 pp | 0.00% +0.000 pp | USD7.96 +262.6% | 12 qtrs — |
| 46 | BANK OF NEW YORK MELLON CORP | 118.4K +23.7K (+25.0%) | 3.42M +2.7M (+400.5%) | 0.26% +0.052 pp | 0.00% +0.001 pp | USD11.47 +151.6% | 22 qtrs — |
| 47 | SEVEN GRAND MANAGERS, LLC | 100.0K +100.0K (+100.0%) | 2.89M +2.9M (+100.0%) | 0.22% +0.219 pp | 0.22% +0.220 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 48 | SUPERSTRING CAPITAL MANAGEMENT LP | 96.3K +96.3K (+100.0%) | 2.78M +2.8M (+100.0%) | 0.21% +0.211 pp | 1.49% +1.489 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 49 | NUVEEN, LLC | 91.0K +1.9K (+2.1%) | 2.62M +2.0M (+308.7%) | 0.20% +0.004 pp | 0.00% +0.001 pp | USD9.89 +191.8% | 4 qtrs — |
| 50 | OPPENHEIMER & CO INC | 80.8K -54.6K (-40.3%) | 2.33M +1.4M (+138.9%) | 0.18% -0.120 pp | 0.03% +0.021 pp | USD9.45 +205.4% | 7 qtrs — |
| 51 | FRED ALGER MANAGEMENT, LLC | 80.8K +80.8K (+100.0%) | 2.33M +2.3M (+100.0%) | 0.18% +0.177 pp | 0.01% +0.009 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 52 | BLACK DIAMOND FINANCIAL, LLC | 79.1K -198.7K (-71.5%) | 2.28M +279.7K (+14.0%) | 0.17% -0.435 pp | 0.24% +0.016 pp | USD13.80 +109.1% | 5 qtrs — |
| 53 | ANSON FUNDS MANAGEMENT LP | 68.0K +68.0K (+100.0%) | 1.96M +2.0M (+100.0%) | 0.15% +0.149 pp | 0.19% +0.185 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 54 | SIMPLEX TRADING, LLC | 55.7K +55.7K (+100.0%) | 1.61M +1.6M (+100.0%) | 0.12% +0.122 pp | 0.00% +0.001 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 55 | TWO SIGMA INVESTMENTS, LP | 54.8K -301.0K (-84.6%) | 1.58M -984.5K (-38.4%) | 0.12% -0.659 pp | 0.00% -0.002 pp | USD9.17 +214.7% | 9 qtrs — |
| 56 | BANK OF AMERICA CORP /DE/ | 53.8K +11.1K (+25.8%) | 1.55M +1.2M (+403.7%) | 0.12% +0.024 pp | 0.00% +0.000 pp | USD16.18 +78.4% | 15 qtrs — |
| 57 | PERSISTENT ASSET PARTNERS LTD | 51.5K +51.5K (+100.0%) | 1.49M +1.5M (+100.0%) | 0.11% +0.113 pp | 0.67% +0.667 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 58 | JUMP FINANCIAL, LLC | 49.5K +49.5K (+100.0%) | 1.43M +1.4M (+100.0%) | 0.11% +0.108 pp | 0.02% +0.018 pp | USD28.86 +0.0% | 4 qtrs — |
| 59 | RHUMBLINE ADVISERS | 47.0K -3.9K (-7.7%) | 1.36M +988.9K (+269.6%) | 0.10% -0.009 pp | 0.00% +0.001 pp | USD8.09 +256.7% | 7 qtrs — |
| 60 | LPL FINANCIAL LLC | 46.6K +3.9K (+9.1%) | 1.34M +1.0M (+336.8%) | 0.10% +0.009 pp | 0.00% +0.000 pp | USD10.06 +186.9% | 3 qtrs — |
| 61 | WELLS FARGO & COMPANY/MN | 45.6K +5.6K (+14.0%) | 1.32M +1.0M (+356.4%) | 0.10% +0.012 pp | 0.00% +0.000 pp | USD10.04 +187.5% | 23 qtrs — |
| 62 | FARALLON CAPITAL MANAGEMENT LLC | 41.0K +— (+0.0%) | 1.18M +887.7K (+300.3%) | 0.09% +0.000 pp | 0.01% +0.004 pp | USD13.80 +109.1% | 5 qtrs — |
| 63 | ADVISOR GROUP HOLDINGS, INC. | 39.9K +6.7K (+20.3%) | 1.15M +935.5K (+434.2%) | 0.09% +0.015 pp | 0.00% +0.001 pp | USD11.70 +146.7% | 18 qtrs — |
| 64 | ALLIANCEBERNSTEIN L.P. | 38.8K -39.9K (-50.7%) | 1.12M +553.1K (+97.4%) | 0.08% -0.087 pp | 0.00% +0.000 pp | USD10.58 +172.8% | 5 qtrs — |
| 65 | JANE STREET GROUP, LLC | 33.8K -106.6K (-75.9%) | 975.5K -36.8K (-3.6%) | 0.07% -0.233 pp | 0.00% +0.000 pp | USD10.37 +178.3% | 6 qtrs — |
| 66 | GLENMEDE TRUST CO NA | 32.1K +32.1K (+100.0%) | 926.1K +926.1K (+100.0%) | 0.07% +0.070 pp | 0.00% +0.004 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 67 | QUEST PARTNERS LLC | 30.1K +31.0 (+0.1%) | 867.4K +650.9K (+300.7%) | 0.07% +0.000 pp | 0.05% +0.034 pp | USD8.41 +243.2% | 5 qtrs — |
| 68 | DEUTSCHE BANK AG\ | 28.7K +3.6K (+14.5%) | 829.2K +648.3K (+358.4%) | 0.06% +0.008 pp | 0.00% +0.000 pp | USD15.34 +88.1% | 5 qtrs — |
| 69 | ENVESTNET ASSET MANAGEMENT INC | 27.4K +13.7K (+99.4%) | 790.9K +691.8K (+698.2%) | 0.06% +0.030 pp | 0.00% +0.000 pp | USD18.00 +60.3% | 4 qtrs — |
| 70 | COMMONWEALTH EQUITY SERVICES, LLC | 26.3K -4.6K (-14.8%) | 758.7K +535.7K (+240.2%) | 0.06% -0.010 pp | 0.00% +0.001 pp | USD7.45 +287.4% | 8 qtrs — |
| 71 | PRICE T ROWE ASSOCIATES INC /MD/ | 23.2K +2.6K (+12.5%) | 669.0K +520.0K (+349.0%) | 0.05% +0.006 pp | 0.00% +0.000 pp | USD14.21 +103.1% | 5 qtrs — |
| 72 | METLIFE INVESTMENT MANAGEMENT, LLC | 22.0K +7.7K (+54.4%) | 634.2K +531.6K (+517.9%) | 0.05% +0.017 pp | 0.00% +0.003 pp | USD19.10 +51.1% | 5 qtrs — |
| 73 | JAIN GLOBAL LLC | 21.7K +21.7K (+100.0%) | 626.3K +626.3K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.003 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 74 | MARINER, LLC | 21.5K +7.8K (+57.6%) | 619.0K +520.9K (+530.9%) | 0.05% +0.017 pp | 0.00% +0.001 pp | USD15.12 +90.9% | 2 qtrs — |
| 75 | ACADIAN ASSET MANAGEMENT LLC | 20.1K +20.1K (+100.0%) | 579.0K +579.0K (+100.0%) | 0.04% +0.044 pp | 0.00% +0.001 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 76 | FORA CAPITAL, LLC | 20.0K +20.0K (+100.0%) | 576.3K +576.3K (+100.0%) | 0.04% +0.044 pp | 0.07% +0.070 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 77 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 17.9K -82.0 (-0.5%) | 515.5K +386.1K (+298.4%) | 0.04% 0.000 pp | 0.00% +0.001 pp | USD14.57 +98.1% | 6 qtrs — |
| 78 | STEMPOINT CAPITAL LP | 17.9K +17.9K (+100.0%) | 515.2K +515.2K (+100.0%) | 0.04% +0.039 pp | 0.09% +0.088 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 79 | CREATIVE PLANNING | 15.2K +15.2K (+100.0%) | 439.6K +439.6K (+100.0%) | 0.03% +0.033 pp | 0.00% +0.000 pp | USD28.86 +0.0% | 4 qtrs — |
| 80 | ENTROPY TECHNOLOGIES, LP | 14.2K +14.2K (+100.0%) | 408.9K +408.9K (+100.0%) | 0.03% +0.031 pp | 0.02% +0.022 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 81 | INVESCO LTD. | 13.6K -34.0 (-0.2%) | 393.1K +294.7K (+299.3%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD6.46 +346.7% | 7 qtrs — |
| 82 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 13.3K +13.3K (+100.0%) | 383.7K +383.7K (+100.0%) | 0.03% +0.029 pp | 0.01% +0.006 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 83 | NEW YORK STATE COMMON RETIREMENT FUND | 13.0K +7.2K (+124.1%) | 375.2K +333.4K (+797.2%) | 0.03% +0.016 pp | 0.00% +0.000 pp | USD21.59 +33.7% | 7 qtrs — |
| 84 | STATE OF WISCONSIN INVESTMENT BOARD | 12.8K -58.8K (-82.2%) | 368.1K -147.8K (-28.6%) | 0.03% -0.129 pp | 0.00% 0.000 pp | USD7.21 +300.3% | 5 qtrs — |
| 85 | US BANCORP \DE\ | 12.6K +5.2K (+69.3%) | 364.5K +310.7K (+577.5%) | 0.03% +0.011 pp | 0.00% +0.000 pp | USD14.01 +106.0% | 27 qtrs — |
| 86 | SEI INVESTMENTS CO | 12.6K +12.6K (+100.0%) | 363.9K +363.9K (+100.0%) | 0.03% +0.028 pp | 0.00% +0.000 pp | USD28.86 +0.0% | 1 qtrs NEW |
| 87 | QUANTINNO CAPITAL MANAGEMENT LP | 12.4K +12.4K (+100.0%) | 357.5K +357.5K (+100.0%) | 0.03% +0.027 pp | 0.00% +0.001 pp | USD28.86 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 70 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.51% | 295.4K | 0.65% |
| 2 | Global X - S&P Biotech ETF CURE.AX | 0.43% | 155.9K | 0.45% |
| 3 | State Street SPDR S&P Biotech ETF XBI | 0.43% | 46.98M | 0.35% |
| 4 | Vanguard U.S. Momentum Factor ETF VFMO | 0.10% | 1.74M | 0.13% |
| 5 | Pacer WealthShield ETF PWS | 0.09% | 21.7K | 0.60% |
| 6 | Vanguard Global Momentum Factor ETF VMO.TO | 0.08% | 273.5K | 0.38% |
| 7 | Vanguard Russell 2000 Growth ETF VTWG | 0.07% | 1.22M | 0.06% |
| 8 | iShares Russell 2000 Growth ETF IWO | 0.07% | 10.71M | 0.24% |
| 9 | Direxion Daily S&P Biotech Bull 3X Shares LABU | 0.06% | 381.4K | 0.96% |
| 10 | Innovator U.S. Small Cap Managed Floor ETF RFLR | 0.04% | 40.1K | 0.89% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.50
Neutral
Ratio by volume
0.50
Neutral
Buys
2
Sells
4
Shares acquired
61.3K
Shares disposed
122.5K
Cash buys
—
Cash sales
2.00
Net activity
-61,264
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | Krasney Karen | Officer | M-Exempt | D | Stock Option (Right to Buy) | 25,000 | 3.18 | 79.5K | 56,261 | D | ↗ |
| 2026-05-01 | Bergmann Anthony | Officer | M-Exempt | D | Stock Option (Right to Buy) | 25,000 | 3.18 | 79.5K | 116,980 | D | ↗ |
| 2026-04-02 | Sabar Karimah Es | Director | S-Sale | D | Common Stock | 7,529 | 32.00 | 240.9K | 0 | D | ↗ |
| 2026-04-01 | Sabar Karimah Es | Director | M-Exempt | A | Common Stock | 53,735 | 4.86 | 261.2K | 53,735 | D | ↗ |
| 2026-03-31 | Sabar Karimah Es | Director | S-Sale | D | Common Stock | 61,265 | 30.17 | 1.85M | 0 | D | ↗ |
| 2026-03-31 | Krasney Karen | Officer | M-Exempt | D | Stock Option (Right to Buy) | 693 | 1.39 | 963.27 | 2,807 | D | ↗ |
| 2026-03-31 | Bergmann Anthony | Officer | S-Sale | D | Common Stock | 25,000 | 30.13 | 753.2K | 8,223 | D | ↗ |
| 2026-01-05 | Sabar Karimah Es | Director | A-Award | A | Stock Option (Right to Buy) | 15,500 | 24.81 | 384.6K | 15,500 | D | ↗ |
| 2026-01-05 | Musket David B | Director | A-Award | A | Stock Option (Right to Buy) | 15,500 | 24.81 | 384.6K | 15,500 | D | ↗ |
| 2026-01-05 | Marban Linda | Director / Officer | A-Award | A | Restricted Stock Units | 7,500 | 0.00 | — | 7,500 | D | ↗ |
| 2026-01-05 | Litvack Frank | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 24.81 | 1.24M | 50,000 | D | ↗ |
| 2026-01-05 | Krasney Karen | Officer | A-Award | A | Stock Option (Right to Buy) | 22,500 | 24.81 | 558.2K | 22,500 | D | ↗ |
| 2026-01-05 | Kelliher Mike | Director | A-Award | A | Stock Option (Right to Buy) | 15,500 | 24.81 | 384.6K | 15,500 | D | ↗ |
| 2026-01-05 | Gotwals Philip J | Director | A-Award | A | Stock Option (Right to Buy) | 15,500 | 24.81 | 384.6K | 15,500 | D | ↗ |
| 2026-01-05 | DUNBAR GEORGE W JR | Director | A-Award | A | Stock Option (Right to Buy) | 15,500 | 24.81 | 384.6K | 15,500 | D | ↗ |
| 2026-01-05 | Bergmann Anthony | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 24.81 | 620.3K | 25,000 | D | ↗ |
| 2026-01-05 | Auwaerter Paul Gisbert | Director | A-Award | A | Stock Option (Right to Buy) | 15,500 | 24.81 | 384.6K | 15,500 | D | ↗ |
| 2025-12-30 | Krasney Karen | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,500 | 1.39 | 3.5K | 0 | D | ↗ |
| 2025-12-19 | DUNBAR GEORGE W JR | Director | M-Exempt | A | Common Stock | 3,000 | 1.39 | 4.2K | 14,306 | D | ↗ |
| 2025-03-05 | Marban Linda | Director / Officer | J-Other | D | Common Stock | 12,500 | 0.00 | — | 211,104 | D | ↗ |
| 2025-03-03 | Marban Linda | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 25,000 | 1.39 | 34.8K | 0 | D | ↗ |
| 2025-03-03 | Litvack Frank | Director | M-Exempt | A | Common Stock | 25,000 | 1.39 | 34.8K | 132,382 | D | ↗ |
| 2025-03-03 | DUNBAR GEORGE W JR | Director | M-Exempt | D | Stock Option (Right to Buy) | 750 | 1.39 | 1.0K | 0 | D | ↗ |
| 2025-03-03 | Bergmann Anthony | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,500 | 1.39 | 3.5K | 0 | D | ↗ |
| 2025-02-27 | COLLIER EARL M JR | Director | M-Exempt | A | Common Stock | 750 | 1.39 | 1.0K | 57,606 | D | ↗ |
| 2025-01-02 | Sabar Karimah Es | Director | A-Award | A | Stock Option (Right to Buy) | 2,520 | 14.96 | 37.7K | 2,520 | D | ↗ |
| 2025-01-02 | Musket David B | Director | A-Award | A | Stock Option (Right to Buy) | 11,940 | 14.96 | 178.6K | 11,940 | D | ↗ |
| 2025-01-02 | Marban Linda | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 34,962 | 14.96 | 523.0K | 34,962 | D | ↗ |
| 2025-01-02 | Litvack Frank | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 14.96 | 748.0K | 50,000 | D | ↗ |
| 2025-01-02 | Krasney Karen | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 14.96 | 897.6K | 60,000 | D | ↗ |
| 2025-01-02 | Kelliher Mike | Director | A-Award | A | Stock Option (Right to Buy) | 1,440 | 14.96 | 21.5K | 1,440 | D | ↗ |
| 2025-01-02 | Gotwals Philip J | Director | A-Award | A | Stock Option (Right to Buy) | 5,750 | 14.96 | 86.0K | 5,750 | D | ↗ |
| 2025-01-02 | DUNBAR GEORGE W JR | Director | A-Award | A | Stock Option (Right to Buy) | 5,750 | 14.96 | 86.0K | 5,750 | D | ↗ |
| 2025-01-02 | COLLIER EARL M JR | Director | A-Award | A | Stock Option (Right to Buy) | 5,750 | 14.96 | 86.0K | 5,750 | D | ↗ |
| 2025-01-02 | Bergmann Anthony | Officer | A-Award | A | Stock Option (Right to Buy) | 6,170 | 14.96 | 92.3K | 6,170 | D | ↗ |
| 2025-01-02 | Auwaerter Paul Gisbert | Director | A-Award | A | Stock Option (Right to Buy) | 1,440 | 14.96 | 21.5K | 1,440 | D | ↗ |
| 2024-12-13 | Krasney Karen | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 1.39 | 7.0K | 0 | D | ↗ |
| 2024-12-03 | Litvack Frank | Director | M-Exempt | D | Warrants (Right to Buy) | 20,391 | 1.10 | 22.4K | 0 | I | ↗ |
| 2024-12-02 | Litvack Frank | Director | G-Gift | A | Warrants (Right to Buy) | 20,391 | 1.10 | 22.4K | 20,391 | I | ↗ |
| 2024-09-20 | Nippon Shinyaku Co Ltd | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 2,798,507 | 5.36 | 15.00M | 7,090,351 | D | ↗ |
| 2024-08-07 | Musket David B | Director | M-Exempt | D | Stock Option (Right to Buy) | 34,000 | 1.39 | 47.3K | 75,000 | — | ↗ |
| 2024-04-23 | Musket David B | Director | M-Exempt | A | Common Stock | 16,156 | 1.39 | 22.5K | 47,692 | — | ↗ |
| 2024-04-23 | COLLIER EARL M JR | Director | M-Exempt | A | Common Stock | 30,000 | 1.39 | 41.7K | 56,856 | — | ↗ |
| 2024-04-03 | Nippon Shinyaku Co Ltd | 10% Owner | — | D | Warrant (right to buy) | 2,145,922 | 5.70 | 12.23M | 0 | — | ↗ |
| 2024-01-02 | Sabar Karimah Es | Director | A-Award | A | Stock Option (Right to Buy) | 29,250 | 5.12 | 149.8K | 29,250 | — | ↗ |
| 2024-01-02 | Musket David B | Director | A-Award | A | Stock Option (Right to Buy) | 14,280 | 5.12 | 73.1K | 14,280 | — | ↗ |
| 2024-01-02 | Marban Linda | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 5.12 | 1.28M | 250,000 | — | ↗ |
| 2024-01-02 | Litvack Frank | Director | A-Award | A | Stock Option (Right to Buy) | 200,000 | 5.12 | 1.02M | 200,000 | — | ↗ |
| 2024-01-02 | Krasney Karen | Officer | A-Award | A | Stock Option (Right to Buy) | 7,140 | 5.12 | 36.6K | 7,140 | — | ↗ |
| 2024-01-02 | Kelliher Mike | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 5.12 | 153.6K | 30,000 | — | ↗ |
| 2024-01-02 | Gotwals Philip J | Director | A-Award | A | Stock Option (Right to Buy) | 6,370 | 5.12 | 32.6K | 6,370 | — | ↗ |
| 2024-01-02 | DUNBAR GEORGE W JR | Director | A-Award | A | Stock Option (Right to Buy) | 14,280 | 5.12 | 73.1K | 14,280 | — | ↗ |
| 2024-01-02 | COLLIER EARL M JR | Director | A-Award | A | Stock Option (Right to Buy) | 8,030 | 5.12 | 41.1K | 8,030 | — | ↗ |
| 2024-01-02 | Bergmann Anthony | Officer | A-Award | A | Stock Option (Right to Buy) | 9,692 | 5.12 | 49.6K | 9,692 | — | ↗ |
| 2024-01-02 | Auwaerter Paul Gisbert | Director | A-Award | A | Stock Option (Right to Buy) | 29,250 | 5.12 | 149.8K | 29,250 | — | ↗ |
| 2023-10-23 | Bergmann Anthony | Officer | M-Exempt | A | Common Stock | 2,178 | 1.39 | 3.0K | 2,381 | — | ↗ |
| 2023-10-12 | Musket David B | Director | P-Purchase | A | Common Stock | 410 | 2.75 | 1.1K | 31,536 | — | ↗ |
| 2023-10-10 | COLLIER EARL M JR | Director | P-Purchase | A | Common Stock | 10,000 | 2.83 | 28.3K | 26,856 | — | ↗ |
| 2023-10-09 | Musket David B | Director | P-Purchase | A | Common Stock | 5,083 | 2.82 | 14.3K | 31,126 | — | ↗ |
| 2023-10-06 | Auwaerter Paul Gisbert | Director | P-Purchase | A | Common Stock | 5,000 | 2.84 | 14.2K | 5,000 | — | ↗ |
| 2023-10-04 | Musket David B | Director | P-Purchase | A | Common Stock | 2,500 | 2.90 | 7.3K | 26,043 | — | ↗ |
| 2023-09-01 | Kelliher Mike | Director | A-Award | A | Stock Option (Right to Buy) | 115,000 | 6.61 | 760.2K | 115,000 | — | ↗ |
| 2023-08-14 | Litvack Frank | Director | F-InKind | D | Common Stock | 4,364 | 6.61 | 28.8K | 133,269 | — | ↗ |
| 2023-07-21 | Gotwals Philip J | Director | A-Award | A | Stock Option (Right to Buy) | 115,000 | 4.55 | 523.3K | 115,000 | — | ↗ |
| 2023-07-11 | Auwaerter Paul Gisbert | Director | A-Award | A | Stock Option (Right to Buy) | 115,000 | 4.47 | 514.1K | 115,000 | — | ↗ |
| 2023-05-12 | Marban Linda | Director / Officer | M-Exempt | A | Common Stock | 20,749 | 1.39 | 28.8K | 198,604 | — | ↗ |
| 2023-04-17 | Avat Xavier | — | S-Sale | D | Common Stock | 14,772 | 64,258.00 | 949.22M | 0 | — | ↗ |
| 2023-04-05 | Avat Xavier | — | M-Exempt | A | Common Stock | 84,791 | 3.46 | 293.4K | 84,791 | — | ↗ |
| 2023-03-28 | Avat Xavier | — | S-Sale | D | Common Stock | 3,000 | 4.06 | 12.2K | 0 | — | ↗ |
| 2023-02-21 | Manzo Louis | Director | M-Exempt | A | Common Stock | 1,401 | 1.39 | 1.9K | 62,599 | — | ↗ |
| 2023-02-21 | Litvack Frank | Director | M-Exempt | A | Common Stock | 14,027 | 1.39 | 19.5K | 141,800 | — | ↗ |
| 2023-02-14 | DUNBAR GEORGE W JR | Director | M-Exempt | A | Common Stock | 1,401 | 1.39 | 1.9K | 10,556 | — | ↗ |
| 2023-02-14 | COLLIER EARL M JR | Director | M-Exempt | A | Common Stock | 1,401 | 1.39 | 1.9K | 16,856 | — | ↗ |
| 2023-01-03 | Sabar Karimah Es | Director | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.00 | — | 19,000 | — | ↗ |
| 2023-01-03 | Musket David B | Director | A-Award | A | Stock Option (Right to Buy) | 16,620 | 0.00 | — | 16,620 | — | ↗ |
| 2023-01-03 | Marban Linda | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 135,000 | 0.00 | — | 135,000 | — | ↗ |
| 2023-01-03 | Manzo Louis | Director | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.00 | — | 19,000 | — | ↗ |
| 2023-01-03 | Litvack Frank | Director | A-Award | A | Stock Option (Right to Buy) | 185,000 | 0.00 | — | 185,000 | — | ↗ |
| 2023-01-03 | Krasney Karen | Director | A-Award | A | Stock Option (Right to Buy) | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2023-01-03 | DUNBAR GEORGE W JR | Director | A-Award | A | Stock Option (Right to Buy) | 19,000 | 0.00 | — | 19,000 | — | ↗ |
| 2023-01-03 | COLLIER EARL M JR | Director | A-Award | A | Stock Option (Right to Buy) | 11,870 | 0.00 | — | 11,870 | — | ↗ |
| 2023-01-03 | Bergmann Anthony | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 0.00 | — | 85,000 | — | ↗ |
| 2022-11-03 | Krasney Karen | Director | M-Exempt | A | Common Stock | 18,932 | 1.39 | 26.3K | 20,047 | — | ↗ |
| 2022-06-30 | Musket David B | Director | M-Exempt | D | Stock Option (Right to Buy) | 4,645 | 1.39 | 6.5K | 0 | — | ↗ |
| 2022-06-29 | Musket David B | Director | S-Sale | D | Common Stock | 28,215 | 3.77 | 106.4K | 12,747 | — | ↗ |
| 2022-06-29 | Avat Xavier | Director / Officer | P-Purchase | A | Common Stock | 1,500 | 3.76 | 5.6K | 2,000 | — | ↗ |
| 2022-06-27 | Musket David B | Director | S-Sale | D | Common Stock | 17,775 | 4.44 | 78.9K | 40,962 | — | ↗ |
| 2022-05-23 | Avat Xavier | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 370,000 | 0.00 | — | 370,000 | — | ↗ |
| 2022-03-31 | Manzo Louis | Director | M-Exempt | A | Common Stock | 27,904 | 1.39 | 38.8K | 27,904 | — | ↗ |
| 2022-03-29 | DUNBAR GEORGE W JR | Director | M-Exempt | A | Common Stock | 15,455 | 1.39 | 21.5K | 15,455 | — | ↗ |
| 2022-03-08 | COLLIER EARL M JR | Director | M-Exempt | D | Stock Option (Right to Buy) | 15,455 | 0.00 | — | 0 | — | ↗ |
| 2022-01-03 | Sabar Karimah Es | Director | A-Award | A | Stock Option (Right to Buy) | 7,690 | 3.18 | 24.5K | 7,690 | — | ↗ |
| 2022-01-03 | Musket David B | Director | A-Award | A | Stock Option (Right to Buy) | 84,080 | 3.18 | 267.4K | 84,080 | — | ↗ |
| 2022-01-03 | Marban Linda | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 377,830 | 3.18 | 1.20M | 377,830 | — | ↗ |
| 2022-01-03 | Manzo Louis | Director | A-Award | A | Stock Option (Right to Buy) | 83,590 | 3.18 | 265.8K | 83,590 | — | ↗ |
| 2022-01-03 | Litvack Frank | Director | A-Award | A | Stock Option (Right to Buy) | 252,250 | 3.18 | 802.2K | 252,250 | — | ↗ |
| 2022-01-03 | Krasney Karen | Officer | A-Award | A | Stock Option (Right to Buy) | 84,080 | 3.18 | 267.4K | 84,080 | — | ↗ |
| 2022-01-03 | DUNBAR GEORGE W JR | Director | A-Award | A | Stock Option (Right to Buy) | 63,060 | 3.18 | 200.5K | 63,060 | — | ↗ |
| 2022-01-03 | COLLIER EARL M JR | Director | A-Award | A | Stock Option (Right to Buy) | 63,060 | 3.18 | 200.5K | 63,060 | — | ↗ |
| 2022-01-03 | Bergmann Anthony | Officer | A-Award | A | Stock Option (Right to Buy) | 166,980 | 3.18 | 531.0K | 166,980 | — | ↗ |
| 2021-12-27 | Musket David B | Director | M-Exempt | D | Warrants (Right to Buy) | 20,391 | 1.10 | 22.4K | 0 | — | ↗ |
| 2021-07-23 | Sabar Karimah Es | Director | A-Award | A | Stock Option (Right to Buy) | 115,000 | 4.86 | 558.9K | 115,000 | — | ↗ |
| 2021-01-04 | Musket David B | Director | A-Award | A | Stock Option (Right to Buy) | 96,126 | 3.74 | 359.5K | 96,126 | — | ↗ |
| 2021-01-04 | Marban Linda | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 458,693 | 3.74 | 1.72M | 458,693 | — | ↗ |
| 2021-01-04 | Manzo Louis | Director | A-Award | A | Stock Option (Right to Buy) | 72,066 | 3.74 | 269.5K | 72,066 | — | ↗ |
| 2021-01-04 | Litvack Frank | Director | A-Award | A | Stock Option (Right to Buy) | 211,160 | 3.74 | 789.7K | 211,160 | — | ↗ |
| 2021-01-04 | Krasney Karen | Officer | A-Award | A | Stock Option (Right to Buy) | 95,693 | 3.74 | 357.9K | 95,693 | — | ↗ |
| 2021-01-04 | DUNBAR GEORGE W JR | Director | A-Award | A | Stock Option (Right to Buy) | 71,388 | 3.74 | 267.0K | 71,388 | — | ↗ |
| 2021-01-04 | COLLIER EARL M JR | Director | A-Award | A | Stock Option (Right to Buy) | 71,951 | 3.74 | 269.1K | 71,951 | — | ↗ |
| 2021-01-04 | Bergmann Anthony | Officer | A-Award | A | Stock Option (Right to Buy) | 95,693 | 3.74 | 357.9K | 95,693 | — | ↗ |
| 2020-09-24 | Manzo Louis | Director | M-Exempt | D | Stock Option (Right to Buy) | 8,299 | 3.70 | 30.7K | 0 | — | ↗ |
| 2020-07-27 | Marban Linda | Director / Officer | F-InKind | D | Common Stock | 15,652 | 9.81 | 153.5K | 46,715 | — | ↗ |
| 2020-06-05 | Musket David B | Director | A-Award | A | Stock Option (Right to Buy) | 109,000 | 1.39 | 151.5K | 109,000 | — | ↗ |
| 2020-06-05 | Marban Linda | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 368,449 | 1.39 | 512.1K | 368,449 | — | ↗ |
| 2020-06-05 | Manzo Louis | Director | A-Award | A | Stock Option (Right to Buy) | 83,000 | 1.39 | 115.4K | 83,000 | — | ↗ |
| 2020-06-05 | Litvack Frank | Director | A-Award | A | Stock Option (Right to Buy) | 280,935 | 1.39 | 390.5K | 280,935 | — | ↗ |
| 2020-06-05 | Krasney Karen | Officer | A-Award | A | Stock Option (Right to Buy) | 104,908 | 1.39 | 145.8K | 104,908 | — | ↗ |
| 2020-06-05 | DUNBAR GEORGE W JR | Director | A-Award | A | Stock Option (Right to Buy) | 83,000 | 1.39 | 115.4K | 83,000 | — | ↗ |
| 2020-06-05 | COLLIER EARL M JR | Director | A-Award | A | Stock Option (Right to Buy) | 83,000 | 1.39 | 115.4K | 83,000 | — | ↗ |
| 2020-06-05 | Bergmann Anthony | Officer | A-Award | A | Stock Option (Right to Buy) | 120,003 | 1.39 | 166.8K | 120,003 | — | ↗ |
| 2020-02-12 | Musket David B | Director | D-Return | D | Stock Option (Right to Buy) | 15,455 | 3.70 | 57.2K | 0 | — | ↗ |
| 2020-02-12 | Marban Linda | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 41,497 | 1.39 | 57.7K | 41,497 | — | ↗ |
| 2020-02-12 | Manzo Louis | Director | A-Award | A | Stock Option (Right to Buy) | 4,500 | 1.39 | 6.3K | 4,500 | — | ↗ |
| 2020-02-12 | Litvack Frank | Director | D-Return | D | Stock Option (Right to Buy) | 23,750 | 3.25 | 77.2K | 0 | — | ↗ |
| 2020-02-12 | Krasney Karen | Officer | D-Return | D | Stock Option (Right to Buy) | 2,500 | 25.50 | 63.8K | 0 | — | ↗ |
| 2020-02-12 | DUNBAR GEORGE W JR | Director | D-Return | D | Stock Option (Right to Buy) | 750 | 57.80 | 43.4K | 0 | — | ↗ |
| 2020-02-12 | COLLIER EARL M JR | Director | D-Return | D | Stock Option (Right to Buy) | 4,750 | 3.25 | 15.4K | 0 | — | ↗ |
| 2020-02-12 | Bergmann Anthony | Officer | A-Award | A | Stock Option (Right to Buy) | 5,000 | 1.39 | 7.0K | 5,000 | — | ↗ |
| 2019-12-17 | Musket David B | Director | A-Award | A | Common Stock | 20,391 | 1.23 | 25.0K | 22,891 | — | ↗ |
| 2019-12-17 | Manzo Louis | Director | A-Award | A | Common Stock | 20,391 | 1.23 | 25.0K | 36,304 | — | ↗ |
| 2019-12-17 | Litvack Frank | Director | A-Award | A | Common Stock | 20,391 | 1.23 | 25.0K | 20,391 | — | ↗ |
| 2019-08-08 | Musket David B | Director | A-Award | A | Stock Option (right to buy) | 8,750 | 3.25 | 28.4K | 8,750 | — | ↗ |
| 2019-08-08 | Marban Linda | Director / Officer | A-Award | A | Stock Option (right to buy) | 25,000 | 3.25 | 81.3K | 25,000 | — | ↗ |
| 2019-08-08 | Manzo Louis | Director | A-Award | A | Stock Option (right to buy) | 4,500 | 3.25 | 14.6K | 4,500 | — | ↗ |
| 2019-08-08 | Litvack Frank | Director | A-Award | A | Stock Option (right to buy) | 23,750 | 3.25 | 77.2K | 23,750 | — | ↗ |
| 2019-08-08 | Krasney Karen | Officer | A-Award | A | Stock Option (right to buy) | 14,000 | 3.25 | 45.5K | 14,000 | — | ↗ |
| 2019-08-08 | DUNBAR GEORGE W JR | Director | A-Award | A | Stock Option (right to buy) | 5,250 | 3.25 | 17.1K | 5,250 | — | ↗ |
| 2019-08-08 | COLLIER EARL M JR | Director | A-Award | A | Stock Option (right to buy) | 4,750 | 3.25 | 15.4K | 4,750 | — | ↗ |
| 2019-08-08 | Bergmann Anthony | Officer | A-Award | A | Stock Option (right to buy) | 14,000 | 3.25 | 45.5K | 14,000 | — | ↗ |
| 2018-07-24 | Ascheim Deborah | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 1.24 | 62.0K | 50,000 | — | ↗ |
| 2018-01-02 | Smith Rachel | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 1.57 | 78.5K | 50,000 | — | ↗ |
| 2018-01-02 | Musket David B | Director | A-Award | A | Stock Option (right to buy) | 38,000 | 1.57 | 59.7K | 38,000 | — | ↗ |
| 2018-01-02 | Marban Linda | Director / Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 1.57 | 157.0K | 100,000 | — | ↗ |
| 2018-01-02 | Manzo Louis | Director | A-Award | A | Stock Option (right to buy) | 25,500 | 1.57 | 40.0K | 25,500 | — | ↗ |
| 2018-01-02 | Litvack Frank | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 1.57 | 94.2K | 60,000 | — | ↗ |
| 2018-01-02 | Krasney Karen | Officer | A-Award | A | Stock Option (right to buy) | 35,000 | 1.57 | 55.0K | 35,000 | — | ↗ |
| 2018-01-02 | Kazam Joshua A | Director | A-Award | A | Stock Option (right to buy) | 18,000 | 1.57 | 28.3K | 18,000 | — | ↗ |
| 2018-01-02 | DUNBAR GEORGE W JR | Director | A-Award | A | Stock Option (right to buy) | 28,000 | 1.57 | 44.0K | 28,000 | — | ↗ |
| 2018-01-02 | COLLIER EARL M JR | Director | A-Award | A | Stock Option (right to buy) | 30,500 | 1.57 | 47.9K | 30,500 | — | ↗ |
| 2018-01-02 | Bergmann Anthony | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 1.57 | 78.5K | 50,000 | — | ↗ |
| 2018-01-02 | Ascheim Deborah | Officer | A-Award | A | Stock Option (right to buy) | 43,122 | 1.57 | 67.7K | 43,122 | — | ↗ |
| 2017-12-31 | Kazam Joshua A | Director | — | I | Common Stock | 0 | 0.00 | — | 3,310 | — | ↗ |
| 2017-12-22 | Smith Rachel | Officer | M-Exempt | D | Stock Option (right to buy) | 20,748 | 0.16 | 3.3K | 0 | — | ↗ |
| 2017-10-23 | Manzo Louis | Director | M-Exempt | A | Common Stock | 20,748 | 0.16 | 3.3K | 159,132 | — | ↗ |
| 2017-05-09 | Musket David B | Director | P-Purchase | A | Common Stock | 25,000 | 3.10 | 77.5K | 25,000 | — | ↗ |
| 2017-05-09 | Manzo Louis | Director | P-Purchase | A | Common Stock | 10,000 | 3.10 | 31.0K | 138,384 | — | ↗ |
| 2017-05-09 | CEDARS SINAI MEDICAL CENTER | 10% Owner | P-Purchase | A | Common Stock | 1,145,161 | 3.10 | 3.55M | 4,049,959 | — | ↗ |
| 2017-01-03 | Smith Rachel | Officer | A-Award | A | Stock Option (right to buy) | 35,000 | 2.55 | 89.3K | 35,000 | — | ↗ |
| 2017-01-03 | Musket David B | Director | A-Award | A | Stock Option (right to buy) | 36,060 | 2.55 | 92.0K | 36,060 | — | ↗ |
| 2017-01-03 | Marban Linda | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 2.55 | 510.0K | 200,000 | — | ↗ |
| 2017-01-03 | Manzo Louis | Director | A-Award | A | Stock Option (right to buy) | 23,560 | 2.55 | 60.1K | 23,560 | — | ↗ |
| 2017-01-03 | Litvack Frank | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 2.55 | 63.8K | 25,000 | — | ↗ |
| 2017-01-03 | Krasney Karen | Officer | A-Award | A | Stock Option (right to buy) | 25,000 | 2.55 | 63.8K | 25,000 | — | ↗ |
| 2017-01-03 | Kazam Joshua A | Director | A-Award | A | Stock Option (right to buy) | 16,060 | 2.55 | 41.0K | 16,060 | — | ↗ |
| 2017-01-03 | DUNBAR GEORGE W JR | Director | A-Award | A | Stock Option (right to buy) | 26,060 | 2.55 | 66.5K | 26,060 | — | ↗ |
| 2017-01-03 | COLLIER EARL M JR | Director | A-Award | A | Stock Option (right to buy) | 28,560 | 2.55 | 72.8K | 28,560 | — | ↗ |
| 2017-01-03 | Bergmann Anthony | Officer | A-Award | A | Stock Option (right to buy) | 35,000 | 2.55 | 89.3K | 35,000 | — | ↗ |
| 2017-01-03 | Ascheim Deborah | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 2.55 | 127.5K | 50,000 | — | ↗ |
| 2016-12-31 | Marban Linda | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 3,099,154 | — | ↗ |
| 2016-12-31 | Marban Eduardo | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 199,509 | — | ↗ |
| 2016-09-21 | CEDARS SINAI MEDICAL CENTER | 10% Owner | P-Purchase | A | Common Stock | 312,500 | 3.20 | 1.00M | 2,904,798 | — | ↗ |
| 2016-06-02 | Smith Rachel | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 3.12 | 156.0K | 50,000 | — | ↗ |
| 2016-06-02 | Musket David B | Director | A-Award | A | Stock Option (right to buy) | 46,458 | 3.12 | 144.9K | 46,458 | — | ↗ |
| 2016-06-02 | Manzo Louis | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 3.12 | 93.6K | 30,000 | — | ↗ |
| 2016-06-02 | Litvack Frank | Director | A-Award | A | Stock Option (right to buy) | 39,375 | 3.12 | 122.9K | 39,375 | — | ↗ |
| 2016-06-02 | Krasney Karen | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 3.12 | 156.0K | 50,000 | — | ↗ |
| 2016-06-02 | Kazam Joshua A | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 3.12 | 46.8K | 15,000 | — | ↗ |
| 2016-06-02 | DUNBAR GEORGE W JR | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 3.12 | 93.6K | 30,000 | — | ↗ |
| 2016-06-02 | COLLIER EARL M JR | Director | A-Award | A | Stock Option (right to buy) | 24,375 | 3.12 | 76.1K | 24,375 | — | ↗ |
| 2016-06-02 | Bergmann Anthony | Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 3.12 | 93.6K | 30,000 | — | ↗ |
| 2016-03-16 | St. John Edward A. | 10% Owner | P-Purchase | A | Warrant | 208,333 | 4.50 | 937.5K | 208,333 | — | ↗ |
| 2016-03-16 | Marban Linda | Director / Officer | P-Purchase | A | Warrants (Right to Buy) | 5,076 | 4.50 | 22.8K | 5,076 | — | ↗ |
| 2016-03-16 | Manzo Louis | Director | P-Purchase | A | Common Stock | 100,000 | 2.40 | 240.0K | 128,384 | — | ↗ |
| 2016-03-16 | Krasney Karen | Officer | P-Purchase | A | Warrants (Right to Buy) | 2,030 | 4.50 | 9.1K | 2,030 | — | ↗ |
| 2016-03-16 | GRASMICK LOUIS J | Director | P-Purchase | A | Warrants (Right to Buy) | 10,152 | 4.50 | 45.7K | 10,152 | — | ↗ |
| 2016-03-16 | GERSHELL LELAND | Officer | P-Purchase | A | Warrants (Right to Buy) | 1,050 | 4.50 | 4.7K | 1,050 | — | ↗ |
| 2016-03-16 | CEDARS SINAI MEDICAL CENTER | 10% Owner | P-Purchase | A | Warrants (Right to Buy) | 208,333 | 4.50 | 937.5K | 208,333 | — | ↗ |
| 2016-03-16 | Bergmann Anthony | Officer | P-Purchase | A | Common Stock | 2,030 | 2.40 | 4.9K | 2,030 | — | ↗ |
| 2016-03-02 | GERSHELL LELAND | Officer | A-Award | A | Stock Option (right to buy) | 166,500 | 2.19 | 364.6K | 166,500 | — | ↗ |
| 2016-02-22 | GERSHELL LELAND | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-12-31 | Marban Linda | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 3,173,354 | — | ↗ |
| 2015-09-18 | Ascheim Deborah | Officer | A-Award | A | Stock Option (right to buy) | 130,000 | 4.34 | 564.2K | 130,000 | — | ↗ |
| 2015-08-20 | GRASMICK LOUIS J | Director | P-Purchase | A | Common Stock | 4,630 | 4.08 | 18.9K | 5,950 | — | ↗ |
| 2015-08-19 | Marban Linda | Director / Officer | P-Purchase | A | Common Stock | 4,200 | 4.42 | 18.6K | 3,173,354 | — | ↗ |
| 2015-08-19 | Marban Eduardo | 10% Owner | P-Purchase | A | Common Stock | 4,200 | 4.42 | 18.6K | 268,557 | — | ↗ |
| 2015-08-19 | GRASMICK LOUIS J | Director | P-Purchase | A | Common Stock | 1,320 | 4.22 | 5.6K | 1,320 | — | ↗ |
| 2015-08-18 | Marban Linda | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 4.31 | 21.6K | 264,357 | — | ↗ |
| 2015-08-18 | Marban Eduardo | 10% Owner | P-Purchase | A | Common Stock | 5,000 | 4.31 | 21.6K | 3,169,154 | — | ↗ |
| 2015-08-03 | Ascheim Deborah | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-03-03 | SCHAFER GREGORY W | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 5.78 | 101.2K | 17,500 | — | ↗ |
Executive team
Top executives
Shares Outstanding
45.72M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Linda Marbán, Ph.D. Chief Executive Officer | 300.0K | 270.0K | — | 2.94M | — | 10.6K | 3.52M | 83.51% | ↗ |
| 2 | 2025 | Anthony Bergmann, M.B.A. Chief Financial Officer | 425.0K | 148.8K | 50.0K | 1.04M | — | 11.0K | 1.67M | 65.00% | ↗ |
| 3 | 2025 | Karen Krasney, J.D. Executive Vice President & General Counsel | 391.8K | 98.0K | — | 768.8K | — | 11.0K | 1.27M | 60.56% | ↗ |
| 4 | 2024 | Linda Marbán, Ph.D. Chief Executive Officer | 229.3K | 150.7K | — | 1.15M | — | 9.9K | 1.54M | 74.68% | ↗ |
| 5 | 2024 | Anthony Bergmann, M.B.A. Chief Financial Officer | 376.7K | 150.7K | — | 391.0K | — | 11.9K | 930.2K | 42.03% | ↗ |
| 6 | 2024 | Karen Krasney, J.D. Executive Vice President & General Counsel | 376.7K | 113.0K | — | 368.0K | — | 11.9K | 869.6K | 42.32% | ↗ |
| 7 | 2023 | Linda Marbán, Ph.D. Chief Executive Officer | 220.5K | 77.1K | — | 466.7K | — | 10.0K | 774.3K | 60.27% | ↗ |
| 8 | 2023 | Anthony Bergmann, M.B.A. Chief Financial Officer | 362.3K | 90.5K | — | 293.8K | — | 11.4K | 758.0K | 38.77% | ↗ |
| 9 | 2023 | Karen Krasney, J.D. Executive Vice President & General Counsel | 362.3K | 72.4K | — | 276.6K | — | 12.1K | 723.3K | 38.24% | ↗ |
| 10 | 2022 | Linda Marbán, Ph.D. Chief Executive Officer | 210.0K | 63.0K | — | 1.05M | — | 9.3K | 1.33M | 78.83% | ↗ |
| 11 | 2022 | Anthony Bergmann, M.B.A. Chief Financial Officer | 345.0K | 103.5K | — | 464.5K | — | 10.7K | 923.7K | 50.29% | ↗ |
| 12 | 2022 | Karen Krasney, J.D. Executive Vice President & General Counsel | 345.0K | 78.5K | — | 233.9K | — | 11.0K | 668.4K | 34.99% | ↗ |
| 13 | 2021 | Linda Marbán, Ph.D. Chief Executive Officer | 200.0K | 68.7K | — | 1.50M | — | 25.1K | 1.79M | 83.59% | ↗ |
| 14 | 2021 | Linda Marbán, Ph.D. Chief Executive Officer Karen Krasney, J.D. Executive Vice President & General Counsel Anthony Bergmann, M.B.A. Chief Financial Officer | 200.0K | 68.7K | — | 1.50M | — | 18.5K | 1.78M | 83.90% | ↗ |
| 15 | 2021 | Anthony Bergmann, M.B.A. Chief Financial Officer | 315.0K | 75.0K | — | 312.2K | — | 15.7K | 718.0K | 43.49% | ↗ |
| 16 | 2021 | Karen Krasney, J.D. Executive Vice President & General Counsel | 330.8K | 33.1K | — | 312.2K | — | 10.2K | 686.3K | 45.50% | ↗ |
| 17 | 2020 | Linda Marbán, Ph.D. Chief Executive Officer Karen Krasney, J.D. Executive Vice President & General Counsel Anthony Bergmann Chief Financial Officer | 287.5K | 27.5K | — | 475.7K | — | 1.5K | 792.2K | 60.05% | ↗ |
| 18 | 2020 | Linda Marbán, Ph.D. Chief Executive Officer Karen Krasney, J.D. Executive Vice President & General Counsel Anthony Bergmann, M.B.A. Chief Financial Officer | 313.8K | 31.5K | — | 415.9K | — | 1.5K | 762.6K | 54.53% | ↗ |
| 19 | 2019 | Linda Marbán, Ph.D. Chief Executive Officer Karen Krasney, J.D. Executive Vice President & General Counsel Anthony Bergmann Chief Financial Officer | 156.9K | — | — | 70.5K | — | 1.5K | 228.9K | 30.80% | ↗ |
| 20 | 2018 | Linda Marbán, Ph.D. Chief Executive Officer Karen Krasney, J.D. Executive Vice President & General Counsel | 232.9K | — | — | 144.6K | — | — | 377.5K | 38.30% | ↗ |
| 21 | 2018 | Deborah Ascheim, M.D. Former Chief Medical Officer Anthony Bergmann Chief Financial Officer | 244.5K | — | — | 119.4K | — | 2.00 | 364.9K | 32.73% | ↗ |
| 22 | 2018 | Karen Krasney, J.D. Executive Vice President & General Counsel Deborah Ascheim, M.D. Former Chief Medical Officer | 300.0K | — | — | 50.9K | — | 2.00 | 351.9K | 14.46% | ↗ |
| 23 | 2018 | Linda Marbán, Ph.D. Chief Executive Officer Karen Krasney, J.D. Executive Vice President & General Counsel Anthony Bergmann Chief Financial Officer | 300.0K | — | — | 50.9K | — | 1.0K | 351.9K | 14.46% | ↗ |
| 24 | 2018 | Anthony Bergmann Chief Financial Officer | 200.0K | — | — | 72.7K | — | 2.00 | 273.7K | 26.56% | ↗ |
| 25 | 2017 | Linda Marbán, Ph.D. Chief Executive Officer | 232.9K | — | — | 369.2K | — | — | 602.1K | 61.32% | ↗ |
| 26 | 2017 | Deborah Ascheim, M.D. Chief Medical Officer | 255.0K | — | — | 92.3K | — | 1.0K | 348.3K | 26.50% | ↗ |
| 27 | 2017 | Karen Krasney, J.D. Executive Vice President & General Counsel Deborah Ascheim, M.D. Former Chief Medical Officer | 255.0K | — | — | 92.3K | — | 2.00 | 348.3K | 26.50% | ↗ |
| 28 | 2017 | Karen Krasney, J.D. Executive Vice President & General Counsel Deborah Ascheim, M.D. Chief Medical Officer | 262.5K | — | — | 46.2K | — | 1.0K | 309.7K | 14.90% | ↗ |
| 29 | 2017 | Linda Marbán, Ph.D. Chief Executive Officer Karen Krasney, J.D. Executive Vice President & General Counsel | 262.5K | — | — | 46.2K | — | 2.00 | 309.7K | 14.90% | ↗ |
| 30 | 2017 | Deborah Ascheim, M.D. Former Chief Medical Officer Anthony Bergmann Chief Financial Officer | 154.5K | — | — | 64.6K | — | 2.00 | 220.1K | 29.35% | ↗ |
| 31 | 2016 | Leland Gershell, M.D., Ph.D. Chief Financial Officer | 214.1K | — | — | 263.1K | — | — | 477.2K | 55.13% | ↗ |
| 32 | 2016 | Linda Marbán, Ph.D. Chief Executive Officer Karen Krasney, J.D. Executive Vice President & General Counsel | 259.4K | — | — | 113.5K | — | 1.0K | 373.9K | 30.36% | ↗ |
| 33 | 2016 | Karen Krasney, J.D. Executive Vice President & General Counsel | 259.4K | — | — | 113.5K | — | 1.0K | 373.9K | 30.36% | ↗ |
| 34 | 2016 | Karen Krasney, J.D. Executive Vice President & General Counsel Deborah Ascheim, M.D. Chief Medical Officer | 250.0K | — | — | — | — | 1.0K | 250.3K | 0.00% | ↗ |
| 35 | 2016 | Linda Marbán, Ph.D. Chief Executive Officer | 232.9K | — | — | — | — | — | 232.9K | 0.00% | ↗ |
| 36 | 2015 | Linda Marbán, Ph.D. Chief Executive Officer Karen Krasney, J.D. Executive Vice President & General Counsel Deborah Ascheim, M.D. Chief Medical Officer | 232.9K | — | — | 1.07M | — | — | 1.30M | 82.12% | ↗ |
| 37 | 2015 | Linda Marbán, Ph.D. Chief Executive Officer | 232.9K | — | — | 1.07M | — | — | 1.30M | 82.12% | ↗ |
| 38 | 2015 | Linda Marbán, Ph.D. Chief Executive Officer Karen Krasney, J.D. Executive Vice President & General Counsel | 254.2K | — | — | 128.4K | — | 1.0K | 383.6K | 33.47% | ↗ |
| 39 | 2014 | Andrew Hamer, M.D. Vice President of Medical Affairs | 243.8K | — | — | — | — | 1.0K | 244.8K | 0.00% | ↗ |
| 40 | 2014 | Karen Krasney, J.D. Executive Vice President General Counsel | 232.9K | — | — | — | — | — | 232.9K | 0.00% | ↗ |
| 41 | 2014 | Linda Marbán, Ph.D. Chief Executive Officer Karen Krasney, J.D. Executive Vice President & General Counsel Deborah Ascheim, M.D. Chief Medical Officer | 232.9K | — | — | — | — | — | 232.9K | 0.00% | ↗ |
| 42 | 2013 | Linda Marbán, Ph.D. Chief Executive Officer | 232.3K | — | — | 108.2K | — | — | 340.5K | 31.77% | ↗ |
| 43 | 2013 | Karen Krasney, J.D. Executive Vice President General Counsel | 232.3K | — | — | 108.0K | — | — | 340.3K | 31.73% | ↗ |
| 44 | 2013 | Darlene Horton, M.D. Former Chief Executive Officer | 213.1K | — | — | 49.3K | — | 40.6K | 302.9K | 16.27% | ↗ |
| 45 | 2013 | Karen Krasney, J.D. Executive Vice President General Counsel | 189.4K | — | — | — | — | 1.0K | 190.4K | 0.00% | ↗ |
| 46 | 2013 | Anthony Davies, Ph.D. Former Chief Technology Officer | 189.4K | — | — | — | — | 1.0K | 190.4K | 0.00% | ↗ |
| 47 | 2013 | Andrew Hamer, M.D. Vice President of Medical Affairs | 29.0K | — | — | 24.8K | — | — | 53.7K | 46.08% | ↗ |
| 48 | 2012 | Daron Evans Chief Financial Officer | 275.0K | — | — | — | — | 30.8K | 305.8K | 0.00% | ↗ |
| 49 | 2012 | Linda Marbán, Ph.D. Chief Executive Officer | 190.3K | — | — | — | — | — | 190.3K | 0.00% | ↗ |
| 50 | 2012 | Karen Krasney, J.D. Executive Vice President General Counsel | 130.0K | — | — | 54.7K | — | 1.0K | 185.7K | 29.47% | ↗ |
| 51 | 2012 | Darlene Horton, M.D. President CEO | 81.4K | — | — | — | — | — | 81.4K | 0.00% | ↗ |
| 52 | 2012 | Darlene Horton, M.D. Former Chief Executive Officer | 81.4K | — | — | — | — | — | 81.4K | 0.00% | ↗ |
| 53 | 2012 | Joshua A. Kazam Former President CEO | — | — | — | — | — | — | — | — | ↗ |
| 54 | 2012 | Anthony Davies, Ph.D. Former Chief Technology Officer | — | — | — | — | — | — | — | — | ↗ |
| 55 | 2012 | Richard B. Brewer Former Executive Chairman | — | — | — | — | — | — | — | — | ↗ |
| 56 | 2011 | Daron Evans Chief Financial Officer | 252.1K | 87.5K | — | 20.9K | — | 530.00 | 361.0K | 5.79% | ↗ |
| 57 | 2011 | Richard B. Brewer Former Executive Chairman | 240.0K | — | — | 82.6K | — | — | 322.6K | 25.61% | ↗ |
| 58 | 2011 | Joshua A. Kazam Former President CEO | — | — | — | 35.3K | — | — | 35.3K | 100.00% | ↗ |
| 59 | 2010 | Daron Evans Chief Financial Officer | 226.5K | 75.0K | — | 89.2K | — | 530.00 | 391.2K | 22.79% | ↗ |
| 60 | 2010 | Richard B. Brewer Executive Chairman | 107.4K | — | — | 271.9K | — | — | 379.3K | 71.69% | ↗ |
| 61 | 2010 | Joshua A. Kazam President CEO | — | — | — | 16.9K | — | — | 16.9K | 100.00% | ↗ |
| 62 | 2009 | Peter M. Strumph Former CEO, Director | 143.6K | — | — | 54.8K | — | 250.4K | 448.7K | 12.21% | ↗ |
| 63 | 2009 | Hsiao Lieu VP, Clinical Development | 187.5K | 30.8K | — | 130.4K | — | — | 348.6K | 37.40% | ↗ |
| 64 | 2009 | Daron Evans Chief Financial Officer | 200.0K | 20.0K | — | 80.0K | — | 530.00 | 300.6K | 26.63% | ↗ |
| 65 | 2009 | Joshua Kazam CEO, Director | — | — | — | 81.0K | — | — | 81.0K | 100.00% | ↗ |
| 66 | 2009 | Joshua A. Kazam President CEO | — | — | — | 81.0K | — | — | 81.0K | 100.00% | ↗ |
| 67 | 2009 | Richard B. Brewer Executive Chairman | — | — | — | — | — | — | — | — | ↗ |
| 68 | 2008 | Hsiao Lieu VP, Clinical Development | 202.7K | 55.7K | — | 1.01M | — | — | 1.27M | 79.65% | ↗ |
| 69 | 2008 | Hsiao Lieu VP, Clinical Development | 202.7K | 55.7K | — | 227.0K | — | — | 485.4K | 46.77% | ↗ |
| 70 | 2008 | Peter M. Strumph Former CEO, Director | 316.3K | — | — | — | — | 1.2K | 317.5K | 0.00% | ↗ |
| 71 | 2008 | Daron Evans Chief Financial Officer | 175.0K | — | — | — | — | 530.00 | 175.5K | 0.00% | ↗ |
| 72 | 2007 | Allan Gordon Former Chief Executive Officer | 116.1K | 100.0K | — | 961.7K | — | 489.4K | 1.67M | 57.68% | ↗ |
| 73 | 2007 | Peter M. Strumph Former CEO, Director | 179.8K | 70.4K | — | 628.0K | — | 3.5K | 881.7K | 71.22% | ↗ |
| 74 | 2007 | Peter M. Strumph Chief Executive Officer, Director | 179.8K | 70.4K | — | 628.0K | — | 3.5K | 881.7K | 71.22% | ↗ |
| 75 | 2007 | Daron Evans Chief Financial Officer | 154.9K | 55.4K | — | 270.3K | — | 103.2K | 583.7K | 46.30% | ↗ |
| 76 | 2007 | Jennifer Hodge Vice President, Development | 58.0K | 15.2K | — | 35.8K | — | 425.00 | 109.4K | 32.76% | ↗ |
| 77 | 2007 | Hsiao Lieu VP, Clinical Development | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Anthony J. Bergmann | Chief Financial Officer & Corporate Treasurer | 584.8K | male |
| Linda Marbán | Co-Founder, President, Chief Executive Officer & Director | 580.6K | — |
| Karen G. Krasney | Executive Vice President, General Counsel & Secretary | 500.7K | female |
| Frank Isaac Litvack FACC | Executive Chairman of the Board | 120.0K | — |
| Catherine Lee Kelleher | Consultant | — | — |
| Mark Awadalla | Chief Development Officer | — | male |
| Micheal Binks | Chief Medical Officer | — | — |
| Minghao Sun | Senior Vice President of Quality Control, Research & Product Development | — | male |
| Nathaniel Hogan | Director of Biostatistics of Capricor Therapeutics | — | — |
| Kristi A. H. Elliott | Chief Operating & Science Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CAPR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
